Cargando…

SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine — Ohio and Rhode Island, September–November 2022

Detalles Bibliográficos
Autores principales:	Canaday, David H., Oyebanji, Oladayo A., White, Elizabeth M., Bosch, Jürgen, Nugent, Clare, Vishnepolskiy, Igor, Abul, Yasin, Didion, Elise M., Paxitzis, Alexandra, Sundheimer, Nicholas, Ragavapuram, Vaishnavi, Wilk, Dennis, Keresztesy, Debbie, Cao, Yi, St. Denis, Kerri, McConeghy, Kevin W., McDonald, L. Clifford, Jernigan, John A., Mylonakis, Eleftherios, Wilson, Brigid M., King, Christopher L., Balazs, Alejandro B., Gravenstein, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2023
Materias:	Full Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925133/ https://www.ncbi.nlm.nih.gov/pubmed/36701254 http://dx.doi.org/10.15585/mmwr.mm7204a4

Ejemplares similares

Implications of the SARS-CoV-2 subvariants BA.4 and BA.5
por: Rahimi, Farid, et al.
Publicado: (2022)

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Commentary on ‘Implications of the SARS-CoV-2 subvariants BA.4 and BA.5’
por: Khani, Elnaz, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
por: Evans, John P., et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
por: Kimura, Izumi, et al.
Publicado: (2022)

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
por: Tamura, Tomokazu, et al.
Publicado: (2023)

Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
por: Ai, Jingwen, et al.
Publicado: (2022)

Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
por: Tuekprakhon, Aekkachai, et al.
Publicado: (2022)

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
por: Touret, Franck, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
por: Wang, Qian, et al.
Publicado: (2022)

Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
por: Torres, Carolina, et al.
Publicado: (2023)

Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England
por: Elliott, Paul, et al.
Publicado: (2022)

Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa
por: Tegally, Houriiyah, et al.
Publicado: (2022)

Early Detection of SARS-CoV-2 Omicron BA.4 and BA.5 in German Wastewater
por: Wilhelm, Alexander, et al.
Publicado: (2022)

Structural characteristics of the SARS-CoV-2 Omicron lineages BA.1 and BA.2 virions
por: Ma, Xiaoyu, et al.
Publicado: (2023)

The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5
por: Shuai, Huiping, et al.
Publicado: (2023)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody
por: Kumar, Sanjeev, et al.
Publicado: (2022)

Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa
por: Wolter, Nicole, et al.
Publicado: (2022)

Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5
por: Wang, Yanqun, et al.
Publicado: (2023)

Viral load of SARS‐CoV‐2 Omicron BA.5 is lower than that of BA.2 despite the higher infectivity of BA.5
por: Takatsuki, Yuna, et al.
Publicado: (2023)

Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5
por: Tan, Chee-Wah, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
por: Mykytyn, Anna Z., et al.
Publicado: (2022)

SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta
por: van Doremalen, Neeltje, et al.
Publicado: (2022)

Introduction, Spread and Impact of the SARS-CoV-2 Omicron Variants BA.1 and BA.2 in Cyprus
por: Richter, Jan, et al.
Publicado: (2022)

Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants
por: Jian, Fanchong, et al.
Publicado: (2022)

Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab
por: Fujita, Shigeru, et al.
Publicado: (2022)

Evolution of SARS-CoV-2: BA.4/BA.5 Variants Continues to Pose New Challenges
por: Quadir, Neha, et al.
Publicado: (2022)

Variable detection of Omicron-BA.1 and -BA.2 by SARS-CoV-2 rapid antigen tests
por: Osterman, Andreas, et al.
Publicado: (2022)

SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta
por: van Doremalen, Neeltje, et al.
Publicado: (2022)

Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers
por: Nugent, Clare, et al.
Publicado: (2023)

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Ablation of CD8(+) T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3
por: Swaminathan, Srividhya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d94uast6ooidvjfjaamt7igdij